This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
5 Big Drug Stocks That May Continue to Outperform in 2026
by Kinjel Shah
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
AZNNegative Net Change JNJPositive Net Change LLYNegative Net Change AMGNNegative Net Change ABBVPositive Net Change
biotechs pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNNegative Net Change JNJPositive Net Change HALOPositive Net Change
biotechs medical pharmaceuticals
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
by Zacks Equity Research
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
AZNNegative Net Change ANIPNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
by Zacks Equity Research
BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
BMRNPositive Net Change FOLDNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechs medical
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
by Zacks Equity Research
AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
AZNNegative Net Change ANIPNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
by Ahan Chakraborty
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
IONSPositive Net Change KODPositive Net Change MNPRPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
by Zacks Equity Research
CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.
BMYNegative Net Change FOLDNegative Net Change CYTKPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
by Sundeep Ganoria
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
GSKNegative Net Change BMYNegative Net Change MRKNegative Net Change AMGNNegative Net Change GILDNegative Net Change
biotechs medical pharmaceuticals
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
by Ekta Bagri
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
ANIPNegative Net Change EYPTPositive Net Change TNGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
by Zacks Equity Research
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
MRNANegative Net Change ANIPNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
by Zacks Equity Research
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
NVONegative Net Change LLYNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
by Ekta Bagri
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNNegative Net Change JNJPositive Net Change HALOPositive Net Change
biotechs medical pharmaceuticals
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
by Zacks Equity Research
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
SNYNegative Net Change ANIPNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs medical
Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026?
by Zacks Equity Research
Mirum's Livmarli sales surge 70% in the first nine months of 2025. Expanding approvals and commercialization are set to fuel revenue momentum into 2026.
GSKNegative Net Change MIRMPositive Net Change TVTXPositive Net Change
biotechs
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
by Ahan Chakraborty
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
by Zacks Equity Research
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
NVSNegative Net Change QGENNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
by Zacks Equity Research
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
RHHBYNegative Net Change CRMDNegative Net Change PCSANegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
by Zacks Equity Research
Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.
INSMPositive Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechs medical
5 Biotech Stocks to Watch for Potential Upside
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
ARQTPositive Net Change FOLDNegative Net Change PCRXNegative Net Change ANIPNegative Net Change TNGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
by Kanishka Das
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
PFENegative Net Change PBYIPositive Net Change CRMDNegative Net Change
biotechs
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
by Zacks Equity Research
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
GSKNegative Net Change ANIPNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
by Sundeep Ganoria
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change SMMTNegative Net Change
biotechs medical pharmaceuticals vaccines
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
by Zacks Equity Research
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
ANIPNegative Net Change CRMDNegative Net Change RZLTPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
by Zacks Equity Research
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
AZNNegative Net Change ANIPNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs